188 related articles for article (PubMed ID: 25605454)
1. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.
Advani PP; Crozier JA; Perez EA
Biomark Med; 2015; 9(1):35-49. PubMed ID: 25605454
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Ross JS
Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
[TBL] [Abstract][Full Text] [Related]
3. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
4. HER2 testing: current status and future directions.
Perez EA; Cortés J; Gonzalez-Angulo AM; Bartlett JM
Cancer Treat Rev; 2014 Mar; 40(2):276-84. PubMed ID: 24080154
[TBL] [Abstract][Full Text] [Related]
5. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
6. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas.
Hirschmann A; Lamb TA; Marchal G; Padilla M; Diebold J
Am J Clin Pathol; 2012 Dec; 138(6):837-44. PubMed ID: 23161718
[TBL] [Abstract][Full Text] [Related]
8. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
Lee JA; Shaheen M; Walke T; Daly M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
[TBL] [Abstract][Full Text] [Related]
9. Update on HER2 testing for breast and upper gastrointestinal tract cancers.
Ross JS
Biomark Med; 2011 Jun; 5(3):307-18. PubMed ID: 21657840
[TBL] [Abstract][Full Text] [Related]
10. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
Polónia A; Leitão D; Schmitt F
Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
12. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
13. HER2 testing and correlation with efficacy of trastuzumab therapy.
Fornier M; Risio M; Van Poznak C; Seidman A
Oncology (Williston Park); 2002 Oct; 16(10):1340-8, 1351-2; discussion 1352, 1355-8. PubMed ID: 12435204
[TBL] [Abstract][Full Text] [Related]
14. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
15. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
17. [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
Penault-Llorca F; Vincent-Salomon A; MacGrogan G; Roger P; Treilleux I; Valent A; Mathieu MC; Antoine M; Becette V; Bor C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Devouassoux M; Fiche M; Fondrevelle ME; Fridman V; Garbar C; Genin P; Ghnassia JP; Haudebourg J; Laberge-Le Couteulx S; Loussouarn D; Maran-Gonzalez A; Marcy M; Michenet P; Poulet B; Sagan C; Trassard M; Verriele V; Arnould L; Lacroix-Triki M;
Ann Pathol; 2014 Oct; 34(5):352-65. PubMed ID: 25439988
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in HER2 testing may influence therapy eligibility.
Bernasconi B; Chiaravalli AM; Finzi G; Milani K; Tibiletti MG
Breast Cancer Res Treat; 2012 May; 133(1):161-8. PubMed ID: 21901388
[TBL] [Abstract][Full Text] [Related]
19. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
[TBL] [Abstract][Full Text] [Related]
20. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
Grimm EE; Schmidt RA; Swanson PE; Dintzis SM; Allison KH
Am J Clin Pathol; 2010 Aug; 134(2):284-92. PubMed ID: 20660333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
